Research and reviews on GLP-1 receptor agonists

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

08-22-2018 | Retinopathy | Article

Glucagon-like peptide-1 receptor agonists and the risk of incident diabetic retinopathy

Douros A et al. Diabetes Care 2018: dc172280. doi: 10.2337/dc17-2280

08-21-2018 | Dulaglutide | Article

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea: A 52‐week open‐label, randomized phase 3 trial

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

09-14-2018 | Insulin glargine/Lixisenatide | Article

Bedtime-to-morning glucose difference and iGlarLixi in type 2 diabetes: Post hoc analysis of LixiLan-L

Zisman A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0507-0

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-05-2018 | Exenatide | Article

Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial

Jabbour SA et al. Diabetes Care 2018: dc180680. doi: 10.2337/dc18-0680

08-02-2018 | Diabetic foot | Article

The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial

Dhatariya K et al. Diabetes Care 2018: dc181094. doi: 10.2337/dc18-1094

07-28-2018 | Dulaglutide | Article

Durability of glucose-lowering effect of the first administration of dulaglutide: A retrospective, single-center, single-arm study

Matsushita M et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0474-5

07-30-2018 | Medications | Article

Choice of treatment regimen as add-on to insulin in Japanese patients with type 2 diabetes mellitus: Physicians’ perspective in a real-world setting, insight from a web survey

Imai K, Murayama H, Hirose T. Diabetes Ther 2018. doi: 10.1007/s13300-018-0476-3

07-19-2018 | Semaglutide | Article

A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin

Lingvay I et al. Diabetes Care 2018: dc172381. doi: 10.2337/dc17-2381

07-17-2018 | Heart failure | Article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

06-23-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-20-2018 | Ipragliflozin | Article

Ipragliflozin add-on therapy to a GLP-1 receptor agonist in Japanese patients with type 2 diabetes (AGATE): A 52-week open-label study

Ishihara H et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0455-8

06-20-2018 | Cardiovascular outcomes | Article

Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials

Wang Q et al. Diabetes Res Clin Prac 2018; 143: 34–42. doi: 10.1016/j.diabres.2018.06.009